InfuSystem (NSYE:INFU) announced today that it entered into a national sales and marketing agreement with Ventis Pharma.
Rochester Hills, Michigan-based InfuSystem’s partnership with Ventis will focus on sales and marketing for the latter’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. The kit consists of three non-opioid drugs: tetracaine, lidocaine and epinephrine.
Ventis Pharma designed its innovative, long-acting, very low-toxicity products to reduce surgical pain and treat chronic pain conditions safely and effectively. InfuSystem said in a news release that healthcare providers are increasingly turning to such multi-modal pain management approaches.
“We are pleased to partner with Ventis Pharma in providing a complementary pain management solution,” InfuSystem CEO Richard DiIorio said in the release. “Endura-Kit can be used in conjunction with our InfuBLOCK or as a standalone treatment – providing healthcare professionals and patients an exceptional alternative to oral opioid painkillers. The opioid epidemic in North America is a serious health care crisis. InfuSystem and Ventis Pharma are fully committed to doing our part in helping to reduce the use of oral opioids.”
DiIorio added that he believes the agreement provides InfuSystem’s sales team with “an exciting product” that expands the company’s offerings to its customers, generates additional revenue stream and enhances the effectiveness of each sales call, creating what he expects to be a mutually beneficial relationship.
“Endura-Kit provides anesthesiologists, surgeons and CRNAs with a better option than the current non-opioid post-op local anesthetic products currently available in the market,” Ventis Pharma CEO Tim Patrick said. “We look forward to working closely with InfuSystem and are excited to provide our products and services to our mutual healthcare customers and their patients. This partnership illustrates our unwavering commitment to delivering better medicine to more people while improving the patient’s healthcare experience.”
